Actively Recruiting
Evaluating Safety and Effects of Intravenous ABBV-253 in Adults with Advanced Solid Tumors Including Lung and Other Cancers
Led by AbbVie · Updated on 2026-10-16
130
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This study evaluates ABBV-253, an investigational drug, for adults with advanced solid tumors including non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, gastroesophageal adenocarcinoma, biliary tract cancer, and ovarian cancer. The trial aims to assess adverse events, changes in disease activity, and how the drug moves through the body over approximately four years. Participants will receive ABBV-253 through intravenous infusion. The study has two parts Part 1 involves dose escalation where participants with eligible cancers receive varying doses of ABBV-253 to find the appropriate dose. Part 2 focuses on dose optimization in participants with non-small cell lung cancer, who are randomly assigned to one of three predefined doses. Treatment and evaluation occur over up to four years. Throughout the study, participants will attend regular hospital or clinic visits for medical assessments, blood tests, and questionnaires to monitor side effects and disease activity. Researchers will track safety outcomes including laboratory tests, vital signs, ECG changes, and tumor responses. Pharmacokinetics and immune response to ABBV-253 will be studied for up to one year, while survival and disease control are followed for up to four years.
CONDITIONS
Brief Title
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here